Abstract-The scavenger receptor class B type I (SR-BI) is a lipoprotein receptor that has been shown to be important in high density lipoprotein cholesterol (HDL-C) metabolism in mice. To determine its role in humans, we have characterized the human SR-BI gene and investigated its genetic variation in 489 white men and women. Five variants were demonstrated: 2 in introns (3 and 5) and 3 in exons (1, 8, and 11). Three variants at exons 1 and 8 and intron 5 with allele frequencies Ͼ0.1 were used to examine associations with lipid or anthropometric variables. The exon 1 variant was significantly (PϽ0.05) associated with increased HDL-C and lower low density lipoprotein cholesterol (LDL-C) values in men, but no associations were observed in women. The exon 8 variant was associated in women with lower LDL-C concentrations (3.05Ϯ0.98 mmol/L and 3.00Ϯ0.93 mmol/L for heterozygotes and homozygotes, respectively) compared with women homozygous for the common allele T he scavenger receptor class B type I (SR-BI) is a multilipoprotein receptor found in the liver and steroidogenic glands of both mice 1 and humans 2,3 (for a review, see Reference 4). The cDNA for human SR-BI (also known as CLA-1) was originally cloned by homology to human CD36 and rat LIMPII, which are members of a family of transmembrane proteins. 5 An independent expression cloning study identified the hamster homologue by its ability to mediate the binding of modified LDL, and it was also shown to bind native LDL. 6 Subsequently, murine SR-BI was shown to mediate the uptake of lipid, but not apoprotein, from HDL into cells, 1 a process described as selective uptake. [7][8][9] This finding established SR-BI as the first HDL transmembrane receptor to be identified and cloned. Further studies of the human homologue demonstrated that it also is a multilipoprotein receptor that binds HDL, LDL, and VLDL. 2,10 Further analysis in vivo in mice and rats has supported a role for SR-BI in cholesterol metabolism. Targeted disruption of apoAI, the major protein component of HDL, leads to an increase in SR-BI expression in the adrenal glands of mice, 11 where HDL-C is used for steroid hormone synthesis. In addition, SR-BI expression levels in the adrenal glands are increased in response to adrenocorticotropic hormone and decreased in response to dexamethasone. 12 Estrogen treatment at high doses in rats greatly reduces SR-BI expression in the liver while it increases SR-BI expression in the adrenal gland and ovarian corpus luteal cells. 13 Transient overexpression of SR-BI in the livers of mice by adenoviral infection leads to a marked reduction in plasma HDL levels and a concomitant increase in plasma LDL/IDL cholesterol levels. 14 Finally, targeted disruption of the SR-BI gene in mice leads to a significant increase in plasma HDL 15,16 and reduced selective uptake of cholesterol from HDL into the liver. 16 Thus, SR-BI has clearly been shown to be a very important player in HDL metabolism in mice. However, although mice have HDL as the major cholesterol-carrying lipopr...
Purpose of review:Niemann-Pick disease type C (NP-C) is a neurovisceral disorder that may be more prevalent than earlier estimates. Diagnosis of NP-C is often delayed; a key aim for clinical practice is to reduce this delay. Recently, substantial progress has been made in the field of NP-C screening and diagnosis, justifying an update to the existing recommendations for clinical practice.Recent findings:New biomarker profiling and genetic analysis technologies are included as first-line diagnostic tests for NP-C. Most diagnoses can now be confirmed by combination of biomarker and genetic analyses. Filipin staining may facilitate diagnosis in uncertain cases. Recommendations are provided for psychiatrists, neuro-ophthalmologists, and radiologists, and on screening within specific at-risk patient cohorts. The NP-C diagnostic algorithm has been updated and simplified.Summary:This publication provides expert recommendations for clinicians who may see patients presenting with the signs and symptoms of NP-C, including general practitioners, pediatricians, neurologists, and psychiatrists.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.